​

United Therapeutics (UTHR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

UTHR Stock Forecast

United Therapeutics (UTHR) stock forecast, based on 25 Wall Street analysts, predicts a 12-month average price target of $412.50, with a high of $425.00 and a low of $400.00. This represents a 44.64% increase from the last price of $285.19.

$200 $250 $300 $350 $400 $450 High: $425 Avg: $412.5 Low: $400 Last Closed Price: $285.19

UTHR Stock Rating

United Therapeutics stock's rating consensus is Buy, based on 25 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (56.00%), 10 Hold (40.00%), 1 Sell (4.00%), and 0 Strong Sell (0.00%).

Buy
Total 25 1 10 14 Strong Sell Sell Hold Buy Strong Buy

UTHR Price Target Upside V Benchmarks

TypeNameUpside
StockUnited Therapeutics44.64%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--7
Avg Price Target--$421.71
Last Closing Price$285.19$285.19$285.19
Upside/Downside--47.87%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25275-115
Mar, 25275-115
Feb, 25275-115
Jan, 25276-116
Dec, 242761117
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 31, 2024Jasper HellwegArgus Research$400.00$362.3610.39%40.26%
Oct 31, 2024Andrew FeinH.C. Wainwright$425.00$361.4017.60%49.02%
Sep 23, 2024Eun YangJefferies$432.00$353.0022.38%51.48%
Aug 28, 2024Hartaj SinghOppenheimer$575.00$362.4558.64%101.62%
Jul 08, 2024Ashwani VermaUBS$370.00$317.1816.65%29.74%
Jun 12, 2024Tiago FauthWells Fargo$350.00$275.7626.92%22.73%
May 02, 2024Hartaj SinghOppenheimer$400.00$255.1456.78%40.26%
Feb 12, 2024Chris ShibutaniGoldman Sachs$215.00$214.740.12%-24.61%
Jan 11, 2023Argus Research$300.00$263.4113.89%5.19%
Dec 06, 2022Morgan Stanley$330.00$276.0719.53%15.71%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 08, 2025UBSBuyBuyhold
Oct 31, 2024H.C. WainwrightBuyBuyhold
Oct 21, 2024OppenheimerUnderperformUnderperformhold
Oct 21, 2024Cowen & Co.BuyBuyhold
Sep 23, 2024UBSUnderperformUnderperformhold
Sep 23, 2024JefferiesBuyBuyhold
Aug 28, 2024OppenheimerOutperformOutperformhold
Aug 20, 2024UBSUnderperformUnderperformhold
Aug 20, 2024Wells FargoOverweightOverweighthold
Jul 25, 2024UBSUnderperformUnderperformhold

Financial Forecast

EPS Forecast

$10 $21 $32 $43 $54 $65 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$11.65$10.60$15.98$21.04$26.44----
Avg Forecast$12.77$11.38$17.52$19.75$24.31$28.54$29.58$39.69$34.70
High Forecast$13.57$12.10$18.72$21.10$28.47$34.53$41.57$61.71$37.76
Low Forecast$11.69$10.42$15.82$18.78$22.59$22.69$17.20$23.50$30.22
Surprise %-8.77%-6.85%-8.79%6.53%8.76%----

Revenue Forecast

$1B $2B $2B $3B $4B $5B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.48B$1.69B$1.94B$2.33B$2.88B----
Avg Forecast$1.46B$1.70B$1.96B$2.29B$2.88B$3.17B$3.37B$3.87B$4.11B
High Forecast$1.53B$1.78B$2.07B$2.33B$2.95B$3.38B$3.38B$3.96B$4.39B
Low Forecast$1.37B$1.59B$1.82B$2.26B$2.84B$2.87B$3.36B$3.78B$3.70B
Surprise %1.57%-0.73%-1.35%1.66%0.02%----

Net Income Forecast

$0 $700M $1B $2B $3B $4B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$514.80M$475.80M$727.30M$984.80M$1.20B----
Avg Forecast$481.19M$484.39M$532.82M$984.80M$1.27B$1.30B$1.29B$1.61B$1.72B
High Forecast$577.43M$581.26M$639.39M$1.18B$1.42B$1.72B$2.07B$3.07B$1.88B
Low Forecast$384.95M$387.51M$426.26M$787.84M$1.12B$1.13B$854.73M$1.17B$1.50B
Surprise %6.98%-1.77%36.50%--5.83%----

UTHR Forecast FAQ

Is United Therapeutics stock a buy?

United Therapeutics stock has a consensus rating of Buy, based on 25 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 10 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that United Therapeutics is a favorable investment for most analysts.

What is United Therapeutics's price target?

United Therapeutics's price target, set by 25 Wall Street analysts, averages $412.5 over the next 12 months. The price target range spans from $400 at the low end to $425 at the high end, suggesting a potential 44.64% change from the previous closing price of $285.19.

How does United Therapeutics stock forecast compare to its benchmarks?

United Therapeutics's stock forecast shows a 44.64% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and underperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for United Therapeutics over the past three months?

  • April 2025: 13.33% Strong Buy, 46.67% Buy, 33.33% Hold, 0% Sell, 6.67% Strong Sell.
  • March 2025: 13.33% Strong Buy, 46.67% Buy, 33.33% Hold, 0% Sell, 6.67% Strong Sell.
  • February 2025: 13.33% Strong Buy, 46.67% Buy, 33.33% Hold, 0% Sell, 6.67% Strong Sell.

What is United Therapeutics’s EPS forecast?

United Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $28.54, marking a 7.94% increase from the reported $26.44 in 2024. Estimates for the following years are $29.58 in 2026, $39.69 in 2027, and $34.7 in 2028.

What is United Therapeutics’s revenue forecast?

United Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $3.17B, reflecting a 10.19% increase from the reported $2.88B in 2024. The forecast for 2026 is $3.37B, followed by $3.87B for 2027, and $4.11B for 2028.

What is United Therapeutics’s net income forecast?

United Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $1.3B, representing an 9.12% increase from the reported $1.2B in 2024. Projections indicate $1.29B in 2026, $1.61B in 2027, and $1.72B in 2028.